Bristol-Myers Squibb Company BDR (BMYB34)

B3
Currency in BRL
323.81
-3.22(-0.98%)
Delayed Data
BMYB34 Scorecard
Full Analysis
Has raised its dividend for 3 consecutive years
Fair Value
Day's Range
323.81323.81
52 wk Range
196.96360.00
Key Statistics
Edit
Bid/Ask
322.88 / 323.66
Prev. Close
327.03
Open
323.81
Day's Range
323.81-323.81
52 wk Range
196.96-360
Volume
1
Average Volume (3m)
170
1-Year Change
37.84%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BMYB34 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Bristol-Myers Squibb Company BDR Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Employees
34100
Market
Brazil

Compare BMYB34 to Peers and Sector

Metrics to compare
BMYB34
Peers
Sector
Relationship
P/E Ratio
−12.6x15.1x−0.6x
PEG Ratio
0.06−0.010.00
Price/Book
6.6x2.5x2.6x
Price / LTM Sales
2.3x3.7x3.1x
Upside (Analyst Target)
-31.8%48.7%
Fair Value Upside
Unlock21.3%7.7%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -4.41
Dividend Yield
2.93%
Industry Median 1.72%
Annualised payout
9.5670
Paid quarterly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

62.41
MRCK34
-0.14%
60.02
N1VO34
-1.20%
80.07
A1MD34
+0.05%
739.80
P1GR34
+2.92%

FAQ

What Is the Bristol Myers Squibb Company BDR (BMYB34) Stock Price Today?

The Bristol Myers Squibb Company BDR stock price today is 323.81

What Stock Exchange Does Bristol Myers Squibb Company BDR Trade On?

Bristol Myers Squibb Company BDR is listed and trades on the B3 stock exchange.

What Is the Stock Symbol for Bristol Myers Squibb Company BDR?

The stock symbol for Bristol Myers Squibb Company BDR is "BMYB34."

Does Bristol Myers Squibb Company BDR Pay Dividends? What’s The Current Dividend Yield?

The Bristol Myers Squibb Company BDR dividend yield is 2.93%.

What Is the Bristol Myers Squibb Company BDR Market Cap?

As of today, Bristol Myers Squibb Company BDR market cap is 655.08B.

What is Bristol Myers Squibb Company BDR Earnings Per Share?

The Bristol Myers Squibb Company BDR EPS is -4.41.

From a Technical Analysis Perspective, Is BMYB34 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.